Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.

Biotechnology

Education

Cydan

Cydan's headquarters in Cambridge, MA, United States

Chris Adams

ShiYin Foo

Imran Babar

Joel S. Marcus

Mette Kirstine Agger

Barbara J. Dalton

Matt McAviney

The Leadership Team at Cydan drives the strategic vision and operational execution of the company's orphan drug acceleration initiatives. Comprising experts in business development, preclinical research, and medical strategy, the team identifies promising therapeutic assets, oversees rigorous de-risking processes, and fosters partnerships to establish successful standalone companies focused on rare diseases. Their collective expertise ensures the effective translation of scientific innovation into viable treatment options.

Leadership Team

The Clinical Operations team at Cydan is responsible for overseeing the planning and execution of clinical trials for emerging orphan drug candidates. This team coordinates between various departments to ensure compliance with regulatory standards, manages timelines and budgets, and liaises with stakeholders to facilitate the successful progression of therapies from preclinical research to clinical development. Their expertise is crucial in transforming promising assets into viable treatment options for underserved patient populations.

Cydan

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations

Offices

Cydan

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations

Offices

Related companies